Business Responsibility and Sustainability Reporting for the FY 2024-25
KOPRAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kopran Ltd filed its annual Business Responsibility and Sustainability Report for FY 2024-25, a SEBI-mandated ESG disclosure that forms part of the company's Annual Report. The company is a pure-play pharmaceutical manufacturer, with Active Pharmaceutical Ingredients (APIs) contributing 57.38% and Formulations 42.62% to turnover; total revenue stood at Rs. 629.6 crore with a net worth of Rs. 431.4 crore, and exports accounted for 67% of sales across 100+ countries. Kopran operates 3 domestic plants and 1 office, employs 796 permanent staff and 228 permanent workers, and holds major global certifications including US FDA, EU GMP, WHO GMP, and MHRA (UK). No fines, penalties, or fatalities were reported during the year; 53 customer complaints were filed with 1 resolved by May 2025. The company has not yet set specific ESG targets with timelines and has not undertaken an independent external assessment of its policies.
This is a routine regulatory compliance filing and is unlikely to move the stock on its own. For shareholders, the key takeaways are positive operational signals — strong export dependence, multiple global regulatory approvals, clean safety record with zero fatalities, and no regulatory penalties. The absence of quantified ESG targets and no independent assurance are minor governance gaps to track in future reports.